Previous 10 | Next 10 |
—Incremental updates in LAD-I and PKD and previously disclosed data in FA to be presented— —Clinical updates across all programs anticipated later in Q4— Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing a...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Gaurav Shah, M.D., chief executive officer, will deliver an in-person company presentation a...
Rocket Pharmaceuticals, Inc. is a clinical-stage, multi-platform biotechnology company developing gene therapies with a focus on direct on-target mechanisms of action for rare and devastating orphan diseases. Rocket Pharmaceuticals currently has five ongoing gene-therapy clinical prog...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announced that Gaurav Shah, M.D., chief executive officer, will participate in a fireside chat on Tuesday, ...
— Previously disclosed positive data from the low-dose (6.7e13 vg/kg) cohort of the ongoing Phase 1 trial presented at HFSA’s Annual Scientific Meeting 2021 — — Data demonstrated RP-A501 was well tolerated and showed increasing and durable benefit &...
—Oral presentation on previously disclosed data from the ongoing Phase 1 trial of RP-A501— Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorde...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the appointment of Isabel Carmona, J.D., as chief human resources officer and senior vice pre...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces a securities purchase agreement with a fund affiliated with RTW Investments, LP, the Company’s...
— Initiation of Pediatric Patient Dosing of RP-A501 Expected in Q3 — — Comprehensive Clinical Update from Phase 1 Clinical Trial Planned for Q4 — Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integr...
The following slide deck was published by Rocket Pharmaceuticals, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Rocket Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a le...
2024-06-02 14:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...